Although the mechanisms for reduction of those point mutations with defective NHEJ in vivo are also unknown, their findings are consistent with our finding of reduced BCR-ABL mutations upon inhibiting NHEJ in the KCL-22 CML cell model. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.